Anti-diabetic compounds and Obesity Peptides

Anti-diabetic compounds & obesity peptides – Novel approaches for Diabetes & Obesity Research

Diabetes & obesity has reached epidemic proportions worldwide and is a major contributor to the global burden of various other chronic diseases such as coronary artery diseases, myocardial infarction, hypertension, dyslipidemia and number of other complicated disorders. Diabetes mellitus is clinically characterized by a marked increase in blood glucose levels and is associated with mild hyperlipidemia & obesity is the accumulation of body fat to the extent where it leads to reduced life expectancy & other severe health problems including type 2 diabetes. Significant amount of work has been done towards the development of preventive and therapeutic strategies against diabetes & obesity. Some of the recent research approaches include receptors targeting, islet cell transplantation, gene expression profiling, glucagon-like peptide-1, dipeptidyl peptidase IV inhibitors, insulin therapy, modulators of peroxisome proliferator-activated receptors (PPAR), glucagon receptor antagonists, insulin analogues, ghrelin, peptide YY and combination therapies.

BioVision offers diverse range of high-quality anti-diabetic compounds & obesity peptides for both in vitro & in vivo research.

Anti-diabetic compounds and Obesity Peptides Products